MOH (Israel)

The Israel Ministry of Health (משרד הבריאות — Misrad HaBriut) — operating through the Pharmaceutical Administration (אגף הרוקחות — Agaf HaRokchut), the Institute for Standardization and Control of Pharmaceuticals (ISCP), the Medical Devices and Accessories Division (AMAR), the Israel Pharmacovigilance Centre, the Public Health Services, the National Food Service, and the Central Laboratories in Jerusalem + Tel HaShomer + Abu Kabir — is the State of Israel's national regulatory authority for human medicines + biologicals + biosimilars + advanced therapy medicinal products + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances + clinical trials. The MoH operates under the Pharmacists Ordinance (New Version) 1981 + Pharmacists Regulations (Medicinal Preparations) 1986 + Public Health Ordinance + Medical Devices Law 5772-2012 + Medical Devices Regulations 2013 + Cosmetics Regulations + Dangerous Drugs Ordinance + Israel National Health Insurance Law 5754-1994 + Public Health Regulations (Clinical Trials) 1980 + MoH Director-General Circulars + Pharmaceutical Administration Procedures (Nohalim) + ISCP Guidance Documents.

MoH organisational structure includes:

• Minister of Health (שר הבריאות) — political head; appointed by the Prime Minister.
• Director-General of the Ministry of Health (מנכ"ל משרד הבריאות) — senior civil-service head; appointed by the Minister.
• Deputy Director-General for Health Services + Deputy Director-General for Public Health Services + Deputy Director-General for Pharmaceutical Affairs.
• Pharmaceutical Administration (אגף הרוקחות) — Director-led; responsible for drug + biological + biosimilar + vaccine + ATMP + generic-medicine registration + Pharmacists Ordinance enforcement.
• Institute for Standardization and Control of Pharmaceuticals (ISCP — Makhon Letiyun U'Bakarat Tarukot) — pharmaceutical quality-control laboratory + technical scientific review arm of the Pharmaceutical Administration; ISO/IEC 17025 + WHO PQ-Lab.
• Medical Devices and Accessories Division (AMAR) — medical-device + IVD registration substantively aligned with EU MDR + IVDR.
• Department of Cosmetics + Dietary Supplements — cosmetic-product notification substantively aligned with EU Cosmetics Regulation + dietary-supplement notification.
• Department of Pharmacy Practice — pharmacy + pharmaceutical-establishment licensing.
• Department of Controlled Substances + Dangerous Drugs Division — narcotics + psychotropics coordination with INCB + Israel Police + Israel Customs.
• Israel Pharmacovigilance Centre — WHO PIDM-affiliated; contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Department of Clinical Trials + Helsinki Committee Coordination — CTA + institutional Helsinki Committee (וועדת הלסינקי) + Supreme Helsinki Committee (וועדת הלסינקי העליונה for genetic + ATMP + IVF + embryonic-research trials) coordination per Public Health Regulations (Clinical Trials) 1980.
• Central Laboratories — Jerusalem + Tel HaShomer (Chaim Sheba Medical Center campus — Central Virology Laboratory + National Microbiology Reference Centre) + Abu Kabir (Forensic Institute — toxicology + counterfeit-medicine forensics).
• International Affairs Department — EMA + FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS + PMDA + PIC/S + WHO + ICH + GCC (Abraham Accords) + Arab League + bilateral coordination.

Israel's distinctive global pharmaceutical-innovation context: Israel is one of the most pharmaceutical-innovation-intensive economies globally — Teva Pharmaceutical Industries (headquartered in Petah Tikva) is the world's largest generic-medicines manufacturer + one of the world's largest pharmaceutical companies overall. Israel hosts ~10+ Israeli-domestic manufacturers including Teva + Taro + Dexcel + Perrigo Israel + Trima + Rekah + CTS Chemical Industries + Tzamal Medical + Promedico + Megapharm covering substantial domestic generics + branded + specialty + ophthalmics + dermatology + women's-health + oncology + CNS production. Israel hosts substantial biotechnology + medical-device + digital-health innovation industry — ~500+ Israeli biotechnology + ~700+ Israeli medical-device + ~600+ Israeli digital-health companies with substantial USA + EU export presence + venture-capital flows. Israel's substantial academic-medical-centre clinical-research capacity — Hadassah-Ein Kerem + Hadassah-Mount Scopus + Tel Aviv Sourasky-Ichilov + Sheba Tel HaShomer + Rabin Medical Center-Beilinson + Rambam + Soroka + Carmel + Shaare Zedek + Assuta + Assaf Harofeh + Bnai Zion + the Weizmann Institute + the Technion + Hebrew University-Hadassah + Tel Aviv University + Ben-Gurion University + Bar-Ilan University faculties — makes Israel one of the most operationally significant Phase I-IV clinical-trial hubs globally per-capita.

MoH is distinct from + complementary to: the Israel Pharmacists Association (Histadrut HaRokchim B'Israel — professional licensing body for individual pharmacists); Pharma Israel (Innovative Pharmaceutical Companies Association of Israel); the Israel Pharmaceutical Industry Association (representing generics manufacturers); the Israeli Medical Association (HaHistadrut HaRefuit B'Israel); the four Health Maintenance Organisations (Kupot Holim — Clalit + Maccabi + Meuhedet + Leumit) responsible for substantial pharmaceutical-reimbursement coordination under the National Health Insurance Law via the Health Basket (Sal HaBriut) annual update process led by the Public Committee for Updating the Health Basket; the Israel Innovation Authority (substantial biotechnology + medical-device + digital-health R&D grant funding); and substantial Israeli biopharmaceutical-research infrastructure including Weizmann + Technion + Hebrew University + Tel Aviv University + Ben-Gurion University + Bar-Ilan University + Sheba ARC + Hadassah BioVentures + Rabin Medical Center research-and-development. Israel's pharmaceutical environment is uniquely characterised by: world-leading pharmaceutical-innovation industry with Teva as the world's largest generic-medicines manufacturer; substantial biotechnology + medical-device + digital-health export industry; substantial EU-Israel Association Agreement (2000) + EU-Israel ACAA Protocol on Pharmaceuticals (2012) operational alignment with EMA unique among non-EU non-EEA countries; PIC/S Member status (since 2009 — one of the earliest non-EU PIC/S Members globally); substantial USA + EU + GCC (Abraham Accords 2020 with UAE + Bahrain + Sudan + Morocco) + Arab League + EMRO + sub-Saharan African + Latin American + South-East Asian export markets; substantial Israeli academic-medical-centre clinical-research capacity making Israel one of the most operationally significant Phase I-IV clinical-trial hubs globally per-capita; Hebrew + Arabic + English overlay labelling; Climate Zone II coastal (Tel Aviv + Haifa + Ashdod + Ashkelon + Netanya + Hadera + Mediterranean coast) + IVa Negev interior (Beersheba + Mitzpe Ramon + Eilat) stability requirements.

Israel MoH is a PIC/S Member (since 2009 — one of the earliest non-EU PIC/S Members globally) + WHO PIDM Member + WHO PQ programme participant + maintains substantial EMA bilateral cooperation under the EU-Israel Association Agreement (2000) + the EU-Israel ACAA Protocol on Conformity Assessment and Acceptance of Industrial Products for Pharmaceuticals (2012 — one of only a handful of countries globally with such an arrangement, enabling substantial Israel-EU pharmaceutical mutual-recognition) + substantial FDA + Health Canada + TGA + Swissmedic + MHRA + MFDS + Japanese PMDA + Indian CDSCO + GCC (Abraham Accords) + Arab League bilateral cooperation reflecting Israel's position as a global biotechnology + pharmaceutical-innovation hub.

Israeli pharmaceutical regulation operates under a layered framework of Ordinances + Laws + Regulations + MoH Director-General Circulars + Pharmaceutical Administration Procedures (Nohalim) + ISCP Guidance Documents — substantially aligned with EU pharmaceutical acquis under the EU-Israel Association Agreement (2000) + the EU-Israel ACAA Protocol on Pharmaceuticals (2012):

• Pharmacists Ordinance (New Version) 1981 — foundational pharmaceutical law.
• Pharmacists Regulations (Medicinal Preparations) 1986 — drug registration framework substantively aligned with EU Directive 2001/83/EC.
• Public Health Ordinance (1940, as amended) — overarching public-health framework.
• Medical Devices Law 5772-2012 + Medical Devices Regulations 2013 — substantively aligned with EU MDR 2017/745 + IVDR 2017/746.
• Cosmetics Regulations — substantively aligned with EU Cosmetics Regulation 1223/2009.
• Dangerous Drugs Ordinance (New Version) 1973 — narcotics + psychotropics framework.
• Israel National Health Insurance Law 5754-1994 — Health Basket (Sal HaBriut) reimbursement framework via Public Committee for Updating the Health Basket.
• Public Health Regulations (Clinical Trials in Human Subjects) 1980 — Helsinki Committee + Supreme Helsinki Committee framework.
• Israel MoH GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2.
• Israel MoH GDP Guide — substantively aligned with EU GDP + WHO GDP.
• Israel MoH GCP Guide — substantively aligned with ICH E6(R2) + Israeli Helsinki Committee Procedures.
• Israel MoH GVP Guide — substantively aligned with EU GVP + ICH E2.
• Pharmacopoeia recognition — recognises European Pharmacopoeia + British Pharmacopoeia + USP + Indian Pharmacopoeia + Japanese Pharmacopoeia; no separate Israeli Pharmacopoeia.
• Israeli Essential Medicines List — substantively aligned with WHO Essential Medicines List + Health Basket.
• Variations + 5-year Drug Registration Renewal framework substantively aligned with EU Variations Regulation.
• EU-Israel Association Agreement (2000) + EU-Israel ACAA Protocol on Conformity Assessment and Acceptance of Industrial Products for Pharmaceuticals (2012) — substantial EU pharmaceutical mutual-recognition unique among non-EU non-EEA countries.
• Abraham Accords (2020) Pharmaceutical Cooperation — substantial bilateral pharmaceutical cooperation with UAE + Bahrain + Sudan + Morocco enabling substantial GCC + Arab League + EMRO market-access opportunities.

The Institute for Standardization and Control of Pharmaceuticals (ISCP — Makhon Letiyun U'Bakarat Tarukot) is the Israel MoH's central pharmaceutical quality-control laboratory + technical scientific review arm of the Pharmaceutical Administration with substantial ISO/IEC 17025 + WHO PQ-Lab capacity. Israel MoH is a PIC/S Member (since 2009 — one of the earliest non-EU PIC/S Members globally) enabling substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Iran + Argentina + USA-FDA bilateral inspections. The MoH Pharmaceutical Inspection function conducts substantial inspections of Israeli-domestic + foreign manufacturing facilities both domestically + via PIC/S mutual-recognition + bilateral arrangements.

• ISO/IEC 17025 — ISCP operates with substantial ISO/IEC 17025 accredited scope.
• WHO PQ-Lab — ISCP is WHO PQ-Lab participating; substantial WHO PQ programme participation.
• PIC/S Member (since 2009) — one of the earliest non-EU PIC/S Members globally; substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Iran + Argentina + USA-FDA bilateral inspections; one of the most operationally significant Israel MoH capabilities for foreign-manufacturer GMP-inspection coordination.
• Vaccine lot release — ISCP + Central Virology Laboratory (Tel HaShomer / Chaim Sheba Medical Center campus) conduct vaccine lot-release testing for Israeli National Immunisation Programme.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + substantial post-market surveillance + targeted enforcement testing.
• Medical-device + IVD testing — pre-market + post-market quality testing substantively aligned with EU MDR + IVDR via AMAR.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing substantively aligned with EU Cosmetics Regulation.
• Counterfeit-medicine forensics — substantial forensic analytical support via Abu Kabir Forensic Institute toxicology + Israel Police + Israel Customs + WHO Global Surveillance & Monitoring System contributions.
• Central Virology Laboratory (Tel HaShomer) — National Microbiology Reference Centre + substantial vaccine + biological-products + viral-diagnostics capacity.
• Capacity-building — substantial WHO + EMA + USP + bilateral-donor capacity-building programmes + training for Israeli pharmaceutical analysts.
• GMP Inspectorate — substantial PIC/S Member capability for Israeli + foreign manufacturing facility GMP inspections both domestically + via PIC/S mutual-recognition + bilateral arrangements + EU-Israel ACAA Protocol; substantial export-market support for ~10+ Israeli-domestic manufacturers including Teva.
• Israeli domestic manufacturer support — supports world-leading Israeli pharmaceutical industry including Teva Pharmaceutical Industries (world's largest generic-medicines manufacturer) + Taro + Dexcel + Perrigo Israel + Trima + Rekah + CTS Chemical Industries + Tzamal Medical + Promedico + Megapharm.

Israel MoH medical-device + IVD regulation operates through the Medical Devices and Accessories Division (AMAR — Aganfor Medical Accessories and Equipment Registration) under the Medical Devices Law 5772-2012 + Medical Devices Regulations 2013 substantively aligned with EU MDR 2017/745 + IVDR 2017/746 reflecting EU-Israel ACAA Protocol operational implications. Israel hosts substantial medical-device + IVD + digital-health export industry with ~700+ Israeli medical-device + ~600+ Israeli digital-health companies with substantial USA + EU export presence.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR; IVDs classified under separate framework substantively aligned with EU IVDR.
• Israeli Authorised Representative — Israel-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + MoH regulatory interface.
• ISO 13485:2016 — recognised by MoH as QMS evidence framework; substantial Israeli-domestic manufacturer ISO 13485 capacity.
• Reliance pathways — AMAR accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + MFDS + Japan-approval evidence as supporting evidence; CE Mark particularly central given EU-Israel ACAA Protocol operational alignment + FDA 510(k) given substantial USA export market.
• Reliance-track Registration — AMAR operates substantial reliance-track expedited pathway for CE Mark + FDA + Health Canada + TGA + Swissmedic-registered devices substantially reducing registration timeline.
• Post-market vigilance — AMAR operates medical-device adverse-event reporting; reporting timelines substantively aligned with EU MDR + IMDRF Adverse Event Reporting Codes.
• IVD Reactivigilance — AMAR operates IVD reactivigilance reflecting Israel's substantial clinical-laboratory infrastructure including academic-medical-centres + Health Maintenance Organisation networks.
• Cosmetic Notification — cosmetics require MoH Cosmetic Notification + Hebrew labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU Cosmetics Regulation-aligned framework.
• Dietary Supplement Registration — MoH National Food Service Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Digital-Health + Software-as-a-Medical-Device (SaMD) — distinctive Israeli digital-health framework substantively aligned with IMDRF + FDA SaMD guidance; substantial Israeli digital-health export industry.
• Substantial Export-Market Support — MoH AMAR + Israeli ISO 13485 Notified Body designations provide substantial Israeli-domestic manufacturer export-market support to EU + USA + GCC (Abraham Accords) + Arab League + EMRO + sub-Saharan Africa + Latin America + South-East Asia markets via CE Mark + GMP Certificate + Free Sale Certificate + Certificate of Pharmaceutical Product issuance.

Israel MoH operates the Israel Pharmacovigilance Centre under the Pharmaceutical Administration. Israel is a WHO Programme for International Drug Monitoring (PIDM) member + contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Israel Pharmacovigilance Centre coordinates with academic-medical-centres + Health Maintenance Organisations (Clalit + Maccabi + Meuhedet + Leumit) + Israeli Pharmacists Association + Israeli Medical Association + Marketing Authorisation Holders. Israeli pharmacovigilance is uniquely shaped by world-leading pharmaceutical-innovation industry + substantial EU-Israel ACAA Protocol operational alignment + substantial Israeli academic-medical-centre clinical-research capacity + substantial Israeli ATMP-development surveillance commitments.

• Israel Pharmacovigilance Centre — coordinated by the Pharmaceutical Administration.
• WHO PIDM Member — Israel contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• Israeli PV Network — coordinated national network with effector centres in major Israeli academic-medical-centres (Hadassah-Ein Kerem + Hadassah-Mount Scopus + Tel Aviv Sourasky-Ichilov + Sheba Tel HaShomer + Rabin Medical Center-Beilinson + Rambam + Soroka + Carmel + Shaare Zedek + Assuta + Assaf Harofeh + Bnai Zion) + four Health Maintenance Organisations + Israeli Pharmacists Association + Marketing Authorisation Holders.
• ADR Reporting — MoH operates ADR reporting via Israel Pharmacovigilance Centre portal; available for healthcare professionals + consumers + Marketing Authorisation Holders + with substantial healthcare-professional reporting culture given universal Health Maintenance Organisation coverage.
• E2B(R3) ICSR — MoH accepts E2B(R3) format ICSR submissions; 15-day SUSAR reporting timeline for clinical trials + post-market substantively aligned with EU GVP.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2) + EU GVP.
• Risk Management Plans (RMP) — MoH requires ICH E2E + EU GVP-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + ATMPs + high-risk products.
• Active surveillance — Israel Pharmacovigilance Centre operates substantial active-surveillance programmes leveraging substantial Health Maintenance Organisation electronic-health-record data (one of the world's most comprehensive longitudinal EHR datasets per-capita) for COVID-19 vaccines + childhood immunisation + ATMPs + high-risk products — substantial pharmacoepidemiology research output.
• AEFI Surveillance — Israeli vaccine adverse-event surveillance aligned with WHO methodology; central to Israeli National Immunisation Programme.
• Matériovigilance + Cosmétovigilance — AMAR operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics substantively aligned with EU MDR + IVDR + Cosmetics Regulation.
• Counterfeit + substandard medicine surveillance — substantial role given Israel's geographic position as Mediterranean basin crossroads + substantial Abu Kabir Forensic Institute toxicology + counterfeit-medicine forensics capacity.
• EU GVP Operational Alignment — substantial EU GVP operational alignment under EU-Israel Association Agreement + EU-Israel ACAA Protocol on Pharmaceuticals.
• PIC/S Mutual-Recognition — substantial PIC/S Member pharmacovigilance + GMP-inspection mutual-recognition.

• PIC/S Member (since 2009) — one of the earliest non-EU PIC/S Members globally + one of the most operationally significant Israel MoH capabilities; substantial mutual-recognition agreements with EU + UK + Switzerland + Japan + Australia + Canada + Singapore + Indonesia + Malaysia + Korea + Türkiye + Iran + Argentina + USA-FDA bilateral inspections.
• WHO PIDM Member — Israel contributes substantial ADR data to VigiBase via Uppsala Monitoring Centre.
• WHO PQ Programme Participant — Israeli-manufactured medicines + vaccines via WHO PQ enable substantial UN-agency humanitarian procurement + LMIC market access for Israeli-domestic manufacturers notably Teva.
• EU-Israel Association Agreement (2000) — substantial EU operational alignment foundation.
• EU-Israel ACAA Protocol on Conformity Assessment and Acceptance of Industrial Products for Pharmaceuticals (2012) — one of only a handful of countries globally with such an arrangement; substantial Israel-EU pharmaceutical mutual-recognition unique among non-EU non-EEA countries.
• EMA Cooperation — substantial EMA bilateral cooperation under EU-Israel Association Agreement + EU-Israel ACAA Protocol on Pharmaceuticals.
• FDA Bilateral — substantial FDA cooperation reflecting Israel's substantial USA export market + substantial Israeli biotechnology + medical-device + digital-health innovation industry.
• Health Canada + TGA + Swissmedic + MHRA + MFDS Bilateral — Israel MoH maintains substantial Stringent Regulatory Authority bilateral cooperation.
• Japanese PMDA Bilateral — substantial bilateral cooperation reflecting Israel-Japan pharmaceutical + biotechnology cooperation.
• Indian CDSCO Bilateral — substantial trade-driven cooperation reflecting India as substantial generic-medicines + API trade partner.
• Abraham Accords (2020) Bilateral Cooperation — substantial bilateral pharmaceutical cooperation with UAE MoHAP + Bahrain NHRA + Sudanese NMRA + Moroccan DMP enabling substantial GCC + Arab League + EMRO market-access opportunities.
• Jordan JFDA + Egyptian EDA Bilateral — substantial bilateral cooperation under Israel-Jordan Peace Treaty (1994) + Israel-Egypt Peace Treaty (1979) operational frameworks.
• Türkiye TİTCK Bilateral — regional EMEA peer + substantial bilateral cooperation reflecting Mediterranean basin operational coordination.
• ICH Observer + Observer-Pathway-Engagement — substantial ICH guideline implementation in Israeli regulatory practice including ICH Q1-Q14 + E1-E20 + M1-M11 + S1-S12.
• ICDRA + IMDRF + IPRP participation — substantial International Conference of Drug Regulatory Authorities + International Medical Device Regulators Forum + International Pharmaceutical Regulators Programme participation.
• OECD + International Generic and Biosimilar Medicines Association (IGBA) — substantial OECD + international generic + biosimilar cooperation reflecting Israel's OECD membership + world-leading generic-medicines industry.
• Donor + Bilateral Cooperation — substantial bilateral cooperation with USA NIH + EU Horizon Europe + Israel Innovation Authority + bilateral-donor pharmaceutical-regulatory + healthcare programming.

• EU-Israel ACAA Protocol on Pharmaceuticals (2012) under-leveraged — most operationally significant feature of Israeli pharmaceutical market access; substantial Israel-EU pharmaceutical mutual-recognition unique among non-EU non-EEA countries substantially under-leveraged by foreign manufacturers.
• PIC/S Member (since 2009) mutual-recognition under-leveraged — one of the earliest non-EU PIC/S Members globally; substantial mutual-recognition under-leveraged for GMP-inspection coordination.
• Israeli Authorised Representative not properly designated — application rejected at MoH intake or post-approval compliance failure; Israeli Authorised Representative must be Israel-resident legal entity with appropriate licensure.
• Hebrew + Arabic labelling deficiencies — Hebrew required + Arabic required for areas with substantial Arabic-speaking population; many applicants provide insufficient Hebrew/Arabic-language patient leaflet content.
• Israel MoH GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Israel-specific MoH clarifications.
• Israel climate-zone stability data missing — Israel is Climate Zone II coastal (Tel Aviv + Haifa + Ashdod + Ashkelon + Netanya + Hadera + Mediterranean coast) + Climate Zone IVa Negev interior (Beersheba + Mitzpe Ramon + Eilat); requires substantial zonal-specific stability data.
• Health Basket reimbursement coordination not planned — National Health Insurance Law Health Basket (Sal HaBriut) annual update process December-January via Public Committee for Updating the Health Basket frequently under-planned; substantial cost-effectiveness + budget-impact analysis required for inclusion.
• Reliance-track Registration (AMAR medical devices) under-utilised — substantial reliance-track expedited pathway for CE Mark + FDA + Health Canada + TGA + Swissmedic-registered devices substantially reducing registration timeline under-utilised.
• EMA + SRA reliance under-utilised — substantial EMA + Stringent Regulatory Authority reliance substantially under-utilised despite EU-Israel ACAA Protocol operational alignment.
• Abraham Accords pathway under-leveraged — substantial bilateral pharmaceutical cooperation with UAE + Bahrain + Sudan + Morocco enabling substantial GCC + Arab League + EMRO market-access opportunities substantially under-leveraged.
• Helsinki Committee + Supreme Helsinki Committee CTA planning under-resourced — institutional Helsinki Committee + Supreme Helsinki Committee (genetic + ATMP + IVF + embryonic-research) approval process frequently under-planned; substantial Israeli clinical-trial hub role under-leveraged.
• Israeli Health Maintenance Organisation EHR pharmacoepidemiology under-leveraged — substantial Clalit + Maccabi + Meuhedet + Leumit longitudinal EHR data (one of the world's most comprehensive per-capita) substantially under-leveraged for active surveillance + real-world-evidence + pharmacoepidemiology.
• Bioequivalence centres + biowaiver — MoH BE Guidance provides BCS-based biowaivers substantively aligned with EU; applicants frequently submit BE studies where biowaivers would suffice.
• Substantial Israeli export-market support not leveraged — substantial Israeli ISO 13485 Notified Body + MoH GMP Certificate + CE Mark + Free Sale Certificate + Certificate of Pharmaceutical Product capacity substantially under-leveraged for foreign-manufacturer Israeli-localised production + EU + USA + GCC (Abraham Accords) + Arab League + EMRO export markets.
• Substantial Israeli academic-medical-centre clinical-research capacity not leveraged — world-leading per-capita Phase I-IV clinical-trial hub substantially under-leveraged.
• ATMP + digital-health + medical-device + biotechnology innovation industry partnership opportunities not leveraged — substantial Israeli ATMP + digital-health + medical-device + biotechnology innovation industry partnership opportunities substantially under-leveraged.
• Variations strategy not planned — variations procedure substantively similar to EU but with Israel-specific timelines + fee structure.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.

V5 Ultimate provides the operational infrastructure Israeli + foreign-supplier sites need for Pharmacists Ordinance 1981 + Pharmacists Regulations (Medicinal Preparations) 1986 + Medical Devices Law 5772-2012 + Israel MoH GMP + Cosmetics Regulations + EU-Israel Association Agreement + EU-Israel ACAA Protocol on Pharmaceuticals (2012) + PIC/S Member (since 2009) mutual-recognition + WHO PQ programme participation + Israel Pharmacovigilance Centre + Abraham Accords bilateral cooperation + substantial Israeli-domestic manufacturer export-market support to USA + EU + GCC (Abraham Accords) + Arab League + EMRO markets.

• Israel MoH GMP control framework — PIC/S + EU GMP + ICH Q7 + WHO TRS 986 Annex 2-aligned controls with ALCOA+ data-integrity + Israel-specific clarifications + Climate Zone II coastal + IVa Negev interior stability monitoring.
• Israel MoH registration dossier packaging — Israel CTD-aligned dossier structure with Israel Module 1 specifics + Module 3 stability + Hebrew + Arabic + English patient leaflet + Israeli Authorised Representative declarations + Pharmacists Regulations framework + substantial EU Module reuse.
• EU-Israel ACAA Protocol on Pharmaceuticals (2012) workflow — most operationally significant feature; substantial Israel-EU pharmaceutical mutual-recognition packaging unique among non-EU non-EEA countries.
• PIC/S Member (since 2009) mutual-recognition workflow — one of the earliest non-EU PIC/S Members globally; substantial mutual-recognition packaging for GMP-inspection coordination.
• WHO PQ programme workflow — Israeli-manufactured medicines + vaccines WHO PQ submission packaging for substantial UN-agency humanitarian procurement + LMIC market access (notably Teva).
• EMA + SRA reliance workflow — MoH-EMA + MoH-FDA + MoH-Health Canada + TGA + Swissmedic + MHRA + MFDS + PMDA reliance packaging.
• Abraham Accords pathway workflow — distinctive Abraham Accords (2020) bilateral pharmaceutical cooperation packaging with UAE MoHAP + Bahrain NHRA + Sudanese NMRA + Moroccan DMP for substantial GCC + Arab League + EMRO market-access opportunities.
• Health Basket reimbursement coordination workflow — Public Committee for Updating the Health Basket coordination packaging for parallel cost-effectiveness + budget-impact analysis + annual update process December-January.
• Reliance-track AMAR Registration workflow — substantial reliance-track expedited pathway for CE Mark + FDA + Health Canada + TGA + Swissmedic-registered devices packaging.
• Trade-partner reliance workflow (India CDSCO / Türkiye TİTCK / Jordan JFDA / Egyptian EDA) — substantial trade-driven reliance packaging.
• Israeli Authorised Representative workflow — foreign-manufacturer Israeli Authorised Representative designation + role-management + Israel-specific post-market surveillance.
• Israeli clinical-trial workflow — MoH CTA + Hadassah / Tel Aviv Sourasky / Sheba / Rabin / Rambam / Soroka / Carmel / Shaare Zedek / Assuta institutional Helsinki Committee + Supreme Helsinki Committee coordination + Israeli SUSAR reporting via Israel Pharmacovigilance Centre; substantial Israeli clinical-trials hub role — one of the world's most operationally significant per-capita Phase I-IV trial hubs.
• Israel Pharmacovigilance Centre integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Israeli ICSR + Israeli PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + EU GVP operational alignment.
• Health Maintenance Organisation EHR pharmacoepidemiology integration — substantial Clalit + Maccabi + Meuhedet + Leumit longitudinal EHR data integration packaging for active surveillance + real-world-evidence + pharmacoepidemiology (one of the world's most comprehensive per-capita EHR datasets).
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging substantively aligned with EU MDR + IVDR + Cosmetics Regulation.
• Medical-device + IVD + cosmetic + dietary-supplement + digital-health + Software-as-a-Medical-Device workflow — AMAR frameworks dossier packaging + Class I-III classification + ISO 13485 + Israeli Authorised Representative + post-market vigilance.
• ATMP workflow — MoH + Supreme Helsinki Committee ATMP registration packaging substantively aligned with EMA ATMP framework; substantial Israeli ATMP-innovation industry.
• Israeli export-market support workflow — substantial Israeli ISO 13485 Notified Body + MoH GMP Certificate + CE Mark + Free Sale Certificate + Certificate of Pharmaceutical Product capacity packaging for foreign-manufacturer Israeli-localised production + USA + EU + GCC (Abraham Accords) + Arab League + EMRO export markets.
• USA + EU + GCC (Abraham Accords) + Arab League + EMRO regional bridging — for companies operating across USA + EU + GCC + Arab League + EMRO jurisdictions, V5 surfaces MoH + FDA + EMA + UAE MoHAP + Bahrain NHRA + Saudi SFDA + Jordan JFDA + Egyptian EDA + Türkiye TİTCK + Moroccan DMP harmonised dossier-element reuse alongside national-specific extensions.